Since induced pluripotent stem cells (iPSCs) were first produced in 2006 from mouse cells and in 2007 from human cells, scientists have recognized the incredible potential of the cell type, including their utility in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more. Given the financial potential of the cell type, it is important to have strategies for accessing key individuals, events, and iPSC facilities.
[Read more…]
Price-per-Click Costs Reveal Current Levels of Market Competition for iPS Cells
Purpose of Induced Pluripotent Stem Cell (iPSC) Marketing Analysis
An important area to consider for purposes of quantifying and assessing conditions within the iPSC market is marketing costs.
 Because Google now controls over 70% of online searches, Google Adwords is the single best resource available for analyzing both marketing costs and online search behavior within the induced pluripotent stem cell (iPSC) market.  Specifically, this post considers marketing costs for search terms related to iPSCs, using the Google Adwords tool.
[Read more…]
The Market for Induced Pluripotent Stem Cell (iPSC) Research Products – Rate of Entrants, by Year
Are you an executive at a stem cell company that offers induced pluripotent stem cell (iPSC) research products? Or, are you an investor in a company of this type? If so, have you wondered how much market competition exists for your products or services? Have you been curious as to the rate at which this competition is increasing? By focusing on these key points of understanding, you’ll be able to assess the technical attributes that matter, including what opportunities exist for expanding your product line and your customer reach.
iPSC research products have existed since 2006, the year in which Shinya Yamanaka’s team at Kyoto University first produced iPSCs from mouse cells. Â The discovery was a vital advancement in stem cell research, as it allows researchers to obtain pluripotent stem cells without the difficult legal, technical and ethical controversies that have long surrounded deriving cells from embryos. Â Yamanaka and his team reprogrammed adult mouse fibroblasts into iPSCs by introducing four reprogramming factors: Oct4, Sox2, c-Myc and Klf4. Â Subsequent work by James Thomson and colleagues replicated Yamanaka’s success with human cells and revealed additional factors, Nanog and Lin28, which facilitate the reprogramming process.
[Read more…]
FUJIFILM Acquires Cellular Dynamics International (CDI)
TOKYO and MADISON, Wis., March 30, 2015 —Â FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert Palay)Â (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities, announced that the two companies have entered into a agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger. [Read more…]
BioInformant iPS Cell Data Featured on Centre for Commercialization of Regenerative Medicine
BioInformant is excited to share that our induced pluripotent stem cell industry analytics have been featured on the “Signals Blog,” published by the Centre for Commercialization of Regenerative Medicine (CCRM). CCRM is a Canadian, not-for-profit organization supporting the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies.
The post, titled Right Turn: Commercializing iPSCs – Infographics, states:  “The beauty of an infographic (or two) is it speaks for itself.”
